← ANALYST RATINGS · TIPRANKS
Rigel (RIGL): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy2 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $65.00, the highest $85.00, the lowest $43.00. The average is +41.4% from the last price of $45.97.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $54.00 → $55.00+1.9% | Buy | +19.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $56.00 → $54.00−3.6% | Buy | +17.5% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $54.00 → $52.00−3.7% | Buy | +13.1% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $54.00 → $52.00−3.7% | Hold | +13.1% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $55.00 → $53.00−3.6% | Buy | +15.3% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $55.00 → $53.00−3.6% | Buy | +15.3% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $85.00 | Buy | +84.9% | Reiterated | 05.10.26on TipRanks 11:30 | +0.7%next day −4.1% · 5 days +1.7% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $40.00 → $49.00+22.5% | Hold | +6.6% | Reiterated | 17.08.26on TipRanks 07:22 | +0.2%next day +3.4% · 5 days +7.5% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $81.00 → $83.00+2.5% | Buy | +80.6% | Reiterated | 06.08.26on TipRanks 06:05 | −3.0%next day +1.8% · 5 days +2.8% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $43.00 | Hold | −6.5% | Reiterated | 04.08.26on TipRanks Aug 5 09:25 | +1.6%next day +4.8% · 5 days +8.7% | ↗ |
| Farzin Haque★★★★★★★★★★#6078 · hits 55% · avg +7.3% | Jefferies | $42.00 | Buy | −8.6% | Upgrade | 05.11.25on TipRanks 15:55 | +33.0%next day −3.5% · 5 days +4.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Rigel
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $65.00 at a price of $48.15 (+35.0%); now: $65.00 at $45.97 (+41.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 8 | 7 | 3 | 3 | 4 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 4 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.92 (from $0.75 to $1.07). Last quarter: $0.88.
Sales
Next quarter’s sales estimate — $80M (from $75M to $83M). Last quarter: $79M.
Best top-analyst consensus in the sector · Healthcare
About Rigel
- CEO: Raul R. Rodriguez
- Employees: 173
- 611 Gateway Boulevard, South San Francisco, CA, 94080, US
- www.rigel.com
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 52 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗